0001567619-21-014178.txt : 20210729
0001567619-21-014178.hdr.sgml : 20210729
20210729171817
ACCESSION NUMBER: 0001567619-21-014178
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210727
FILED AS OF DATE: 20210729
DATE AS OF CHANGE: 20210729
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dillon Michael P.
CENTRAL INDEX KEY: 0001777415
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38915
FILM NUMBER: 211128631
MAIL ADDRESS:
STREET 1: C/O IDEAYA BIOSCIENCES, INC.
STREET 2: 7000 SHORELINE COURT, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IDEAYA Biosciences, Inc.
CENTRAL INDEX KEY: 0001676725
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474268251
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7000 SHORELINE COURT, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-443-6209
MAIL ADDRESS:
STREET 1: 7000 SHORELINE COURT, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Ideaya Biosciences, Inc.
DATE OF NAME CHANGE: 20160609
4
1
doc1.xml
FORM 4
X0306
4
2021-07-27
0
0001676725
IDEAYA Biosciences, Inc.
IDYA
0001777415
Dillon Michael P.
C/O IDEAYA BIOSCIENCES, INC.
7000 SHORELINE COURT, SUITE 350
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
SVP, Chief Scientific Officer
Common Stock
2021-07-27
4
M
0
5000
6.92
A
103789
D
Common Stock
2021-07-27
4
M
0
5000
4.31
A
108789
D
Common Stock
2021-07-27
4
S
0
10000
25.146
D
98789
D
Stock Option (right to buy)
6.92
2021-07-27
4
M
0
5000
0
D
2030-02-20
Common Stock
5000
39500
D
Stock Option (Right to Buy)
4.31
2021-07-27
4
M
0
5000
0.00
D
2028-02-26
Common Stock
5000
67735
D
The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
This transaction was executed in multiple trades in prices ranging from $24.95 to $25.28, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
/s/ Jason Throne, as Attorney-in-Fact for Michael P. Dillon
2021-07-29